http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022002112-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ad4f34279a795789b163ddb981f3e0e1
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-80
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001174
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2021-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ed48b00849330f9190636a3062d66bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_111fa58fda919fbfd8d05bf2b5460c3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_799034e81f67e08ef32ad42efddd1fe5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b5b26c4236a2ca1afba99708a9538d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b4764942b369022219df512106ca167
publicationDate 2022-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2022002112-A1
titleOfInvention Anti-gpc3 antibody, anti-gpc3 chimeric antigen receptor and gpc3/cd3 bispecific antibody
abstract Provided herein are novel Glypican 3 (GPC3) antibodies or antigen binding fragments and GPC3/CD3 bispecific antibodies. The present application also provides chimeric antigen receptors comprising the antibodies or antigen-binding fragments, related CAR-T cells, and preparation methods and uses of the same. The present application further provides pharmaceutical compositions comprising GPC3 antibodies or antigen binding fragments, related GPC3/CD3 bispecific antibodies, related GPC3 CAR or CAR-T cells, and methods of treating cancer in a subject in need thereof by administering the Glypican 3 (GPC3) antibodies or antigen binding fragments, the bispecific antibodies, the chimeric antigen receptors, the CAR-T cells, or the pharmaceutical compositions. The cancers treated in accordance with the application include Glypican-3-positive cancers.
priorityDate 2020-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017159287-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013070468-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6101690
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402323
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226451206
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395919
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5816
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57199466
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID247704
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409442
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402238
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID208
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5366546
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226437545

Total number of triples: 46.